Third Rock Ventures Launches Casma Therapeutics with $58.5 Million Investment to Harness the Cellular Process of Autophagy to Develop Breakthrough TherapiesCompany is focusing on lysosomal storage disorders, liver and muscle diseases, inflammation and neurodegeneration CAMBRIDGE, Mass., May 3, 2018-- Casma Therapeutics, Inc., a biotechnology company harnessing the natural cellular process of autophagy to design powerful new medicines, launched today with $58.5 million in Series A funding from Third Rock Ventures. Casma is pioneering novel strategies to boost autophagy to arrest or reverse the progression of rare genetic diseases and broader pathologies, including neurodegeneration.